Latest & greatest articles for folic acid

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on folic acid or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on folic acid and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for folic acid

21. [Folic acid supplementation and colorrectal adenoma recurrence: systematic review].

[Folic acid supplementation and colorrectal adenoma recurrence: systematic review]. Observational studies show that folate levels may be associated with the development of adenomas and colorectal cancer, suggesting that folic acid supplementation may have a preventive effect.Systematic review of scientific evidence from randomized placebo-controlled clinical studies to identify the effects of folic acid supplementation on the recurrence of colorectal adenomas.Medline via Pubmed systematic (...) review of randomized clinical trials, double-blind and placebo-controlled and references, specifically to evaluate the effect of acid supplementation on the recurrence of colorectal adenomas.Seven randomized clinical trials that met the inclusion criteria were selected and evaluated for analysis based on pre established criteria.The selected studies do not support that folic acid supplementation is beneficial in recurrence of colorectal adenomas. We observed in some studies differences in risk

2013 Nutricion hospitalaria

22. Completeness of reporting of setting and health worker cadre among trials on antenatal iron and folic acid supplementation in pregnancy: an assessment based on two Cochrane reviews. (PubMed)

Completeness of reporting of setting and health worker cadre among trials on antenatal iron and folic acid supplementation in pregnancy: an assessment based on two Cochrane reviews. Poor reporting of medical trials has triggered the development of trial reporting standards within the scientific community. In addition to a description of the proposed intervention, adequate information about the trial setting and the group of health workers (cadre) delivering the intervention would allow a better (...) understanding of the generalizability of the trial findings, facilitate replication of trial interventions and assist with assessment of trials for inclusion in systematic reviews. This study aims to determine the completeness of reporting for trial setting and cadre among trials included in two Cochrane reviews on iron and folic acid supplementation for women during pregnancy.From the 81 trials included in the two Cochrane reviews, we extracted data on the trial setting, including the facility type

Full Text available with Trip Pro

2013 Systematic Reviews

23. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. (PubMed)

Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Methotrexate (MTX) is a disease modifying antirheumatic drug (DMARD) used as a first line agent for treating rheumatoid arthritis (RA). Pharmacologically, it is classified as an antimetabolite due to its antagonistic effect on folic acid metabolism. Many patients treated with MTX experience mucosal, gastrointestinal, hepatic or haematologic side effects. Supplementation with folic (...) or folinic acid during treatment with MTX may ameliorate these side effects.To identify trials of supplementation with folic acid or folinic acid during MTX therapy for rheumatoid arthritis and to assess the benefits and harms of folic acid and folinic acid (a) in reducing the mucosal, gastrointestinal (GI), hepatic and haematologic side effects of MTX, and (b) whether or not folic or folinic acid supplementation has any effect on MTX benefit.We originally performed MEDLINE searches, from January 1966

Full Text available with Trip Pro

2013 Cochrane

24. Effects of folic acid supplementation on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50 000 individuals

Effects of folic acid supplementation on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50 000 individuals Effects of folic acid supplementation on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50 000 individuals Effects of folic acid supplementation on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50 000 individuals Vollset SE, Clarke R (...) , Lewington S, Ebbing M, Halsey J, Lonn E, Armitage J, Manson JA, Hankey GJ, Spence JD, Galan P, Bonaa KH, Jamison R, Gaziano JM, Guarino P, Baron JA, Logan RF, Giovannucci EL, den Heijer M, Ueland PM, Bennett D, Collins R, Peto R; B-Vitamin Treatment Trialists' Collaboration CRD summary The review concluded that folic acid supplementation did not substantially increase or decrease incidence of site-specific cancer during the first five years of treatment. These conclusions represent a fair reflection

Full Text available with Trip Pro

2013 DARE.

25. Association between maternal use of folic acid supplements and risk of autism spectrum disorders in children. (PubMed)

Association between maternal use of folic acid supplements and risk of autism spectrum disorders in children. Prenatal folic acid supplements reduce the risk of neural tube defects in children, but it has not been determined whether they protect against other neurodevelopmental disorders.To examine the association between maternal use of prenatal folic acid supplements and subsequent risk of autism spectrum disorders (ASDs) (autistic disorder, Asperger syndrome, pervasive developmental disorder (...) -not otherwise specified [PDD-NOS]) in children.The study sample of 85,176 children was derived from the population-based, prospective Norwegian Mother and Child Cohort Study (MoBa). The children were born in 2002-2008; by the end of follow-up on March 31, 2012, the age range was 3.3 through 10.2 years (mean, 6.4 years). The exposure of primary interest was use of folic acid from 4 weeks before to 8 weeks after the start of pregnancy, defined as the first day of the last menstrual period before conception

Full Text available with Trip Pro

2013 JAMA

26. Cancer risk with folic acid supplements: a systematic review and meta-analysis

Cancer risk with folic acid supplements: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2013 DARE.

27. Cohort study: Maternal folic acid supplements associated with reduced autism risk in the child

Cohort study: Maternal folic acid supplements associated with reduced autism risk in the child Maternal folic acid supplements associated with reduced autism risk in the child | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Maternal folic acid supplements associated with reduced autism risk in the child Article Text Aetiology Cohort study Maternal folic acid supplements associated with reduced autism risk in the child Rebecca J Schmidt

Full Text available with Trip Pro

2013 Evidence-Based Medicine (Requires free registration)

28. The effect of folic acid based homocysteine lowering on cardiovascular events in people with kidney disease: systematic review and meta-analysis

The effect of folic acid based homocysteine lowering on cardiovascular events in people with kidney disease: systematic review and meta-analysis The effect of folic acid based homocysteine lowering on cardiovascular events in people with kidney disease: systematic review and meta-analysis The effect of folic acid based homocysteine lowering on cardiovascular events in people with kidney disease: systematic review and meta-analysis Jardine MJ, Kang A, Zoungas S, Navaneethan SD, Ninomiya T (...) , Nigwekar SU, Gallagher MP, Cass A, Strippoli G, Perkovic V CRD summary The authors concluded that folic acid based homocysteine lowering therapy did not reduce cardiovascular events in people with kidney disease, and should not be used as a preventive treatment. Overall, this was a well-conducted review and the conclusion is likely to be reliable. Authors' objectives To evaluate the effect of folic acid based homocysteine lowering on cardiovascular outcomes in people with kidney disease. Searching

2012 DARE.

29. Bias toward the null hypothesis in pregnancy drug studies that do not include data on medical terminations of pregnancy: the folic acid antagonists (PubMed)

Bias toward the null hypothesis in pregnancy drug studies that do not include data on medical terminations of pregnancy: the folic acid antagonists Most studies on safety/risk of drugs in pregnancy consider the proportion of births (but not pregnancy terminations) affected by the drug from all exposed infants. Lack of data on pregnancy terminations could bias results. A computerized database for medications dispensed to pregnant women in southern Israel was linked with records from the district (...) hospital; 84 823 deliveries and 998 medical pregnancy terminations took place; 571 of the women were exposed to folic acid antagonists in the first trimester. When only births were examined, there was no association between folic acid antagonists and fetal malformations. When data on pregnancy terminations were examined and births and pregnancy terminations were combined, there was a significant risk (neural tube defects: odds ratio 18.83, 95% confidence interval 9.24-38.37; cardiovascular defects

2012 EvidenceUpdates

30. Intermittent iron and folic acid supplementation in non-anaemic pregnant women

Intermittent iron and folic acid supplementation in non-anaemic pregnant women WHO | Archived: Intermittent iron and folic acid supplementation in non-anaemic pregnant women Archived This publication and its contents has been superseded by a more recent version. It is here for reference purposes. Please follow WHO Regional websites Access Nutrition Menu Archived: Intermittent iron and folic acid supplementation in non-anaemic pregnant women Guideline Authors : World Health Organization (...) Publication details Number of pages : 26 Publication date : 2012 Languages : English, Farsi, Portuguese, Spanish ISBN : 978 92 4 150201 6 Downloads pdf, 1.20Mb pdf, 661.67kb pdf, 807kb Overview This guideline provides global, evidence-informed recommendations on intermittent iron and folic acid supplementation as a public health intervention for the purpose of improving pregnancy outcomes and reducing maternal anaemia in pregnancy. The guideline will help Member States and their partners in their efforts

2012 World Health Organisation Guidelines

31. Daily iron and folic acid supplementation in pregnant women

Daily iron and folic acid supplementation in pregnant women WHO | Archived: Daily iron and folic acid supplementation in pregnant women Archived This publication and its contents has been superseded by a more recent version. It is here for reference purposes. Please follow WHO Regional websites Access Nutrition Menu Archived: Daily iron and folic acid supplementation in pregnant women Guideline Authors : World Health Organization Publication details Number of pages : 27 Publication date : 2012 (...) Languages : English, Portuguese, Spanish ISBN : 978 92 4 150199 6 Downloads pdf, 1.045Mb pdf, 862.5kb Overview This guideline provides global, evidence-informed recommendations on daily iron and folic acid supplementation in pregnant women as a public health intervention for the purpose of improving pregnancy outcomes and reducing maternal anaemia in pregnancy. The guideline will help Members States and their partners in their efforts to make informed decisions on the appropriate nutrition actions

2012 World Health Organisation Guidelines

32. The effect of folic acid based homocysteine lowering on cardiovascular events in people with kidney disease: systematic review and meta-analysis. (PubMed)

The effect of folic acid based homocysteine lowering on cardiovascular events in people with kidney disease: systematic review and meta-analysis. To systematically review the effect of folic acid based homocysteine lowering on cardiovascular outcomes in people with kidney disease.Systematic review and meta-analysis.Medline, Embase, the Cochrane Library, and ClinicalTrials.gov to June 2011.Randomised trials in people with non-dialysis dependent chronic kidney disease or end stage kidney disease (...) or with a functioning kidney transplant reporting at least 100 patient years of follow-up and assessing the effect of folic acid based homocysteine lowering therapy. No language restrictions were applied.Two reviewers independently extracted data on study setting, design, and outcomes using a standardised form. The primary endpoint was cardiovascular events (myocardial infarction, stroke, and cardiovascular mortality, or as defined by study author). Secondary endpoints included the individual composite components

Full Text available with Trip Pro

2012 BMJ

33. Efficacy of folic acid supplementation in stroke prevention: new insight from a meta-analysis

Efficacy of folic acid supplementation in stroke prevention: new insight from a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

34. Folic acid supplements in pregnancy and severe language delay in children. (PubMed)

Folic acid supplements in pregnancy and severe language delay in children. Prenatal folic acid supplements reduce the risk of neural tube defects and may have beneficial effects on other aspects of neurodevelopment.To examine associations between mothers' use of prenatal folic acid supplements and risk of severe language delay in their children at age 3 years.The prospective observational Norwegian Mother and Child Cohort Study recruited pregnant women between 1999 and December 2008. Data (...) on children born before 2008 whose mothers returned the 3-year follow-up questionnaire by June 16, 2010, were used. Maternal use of folic acid supplements within the interval from 4 weeks before to 8 weeks after conception was the exposure. Relative risks were approximated by estimating odds ratios (ORs) with 95% CIs in a logistic regression analysis.Children's language competency at age 3 years measured by maternal report on a 6-point ordinal language grammar scale. Children with minimal expressive

Full Text available with Trip Pro

2011 JAMA

35. Homocysteine-Lowering and Cardiovascular Disease Outcomes in Kidney Transplant Recipients: Primary Results From the Folic Acid for Vascular Outcome Reduction in Transplantation Trial (PubMed)

Homocysteine-Lowering and Cardiovascular Disease Outcomes in Kidney Transplant Recipients: Primary Results From the Folic Acid for Vascular Outcome Reduction in Transplantation Trial Kidney transplant recipients, like other patients with chronic kidney disease, experience excess risk of cardiovascular disease and elevated total homocysteine concentrations. Observational studies of patients with chronic kidney disease suggest increased homocysteine is a risk factor for cardiovascular disease (...) . The impact of lowering total homocysteine levels in kidney transplant recipients is unknown.In a double-blind controlled trial, we randomized 4110 stable kidney transplant recipients to a multivitamin that included either a high dose (n=2056) or low dose (n=2054) of folic acid, vitamin B6, and vitamin B12 to determine whether decreasing total homocysteine concentrations reduced the rate of the primary composite arteriosclerotic cardiovascular disease outcome (myocardial infarction, stroke, cardiovascular

Full Text available with Trip Pro

2011 EvidenceUpdates

36. Folic acid for fragile X syndrome. (PubMed)

Folic acid for fragile X syndrome. It has been argued that individuals with fragile X syndrome could have low folate levels in their bodies and that supplementing their dietary intake might remediate the adverse developmental and behavioural effects of the condition.To review the efficacy and safety of folic acid in the treatment of people with fragile X syndrome.We searched four databases in November 2010: CENTRAL, PubMed, EMBASE and PsycINFO.Randomised controlled trials.Two review authors (...) design. The duration of follow-up ranged from two months to 12 months and the period on folic acid or placebo ranged from two to eight months. Doses of folic acid ranged from 10 mg to 250 mg per day, 10 mg per day being the most common. Most of the younger patients involved were also taking part in special education programmes (usually involving language and occupational therapy).We were not able to perform meta-analysis to combine results but none of the individual studies found evidence of clinical

2011 Cochrane

37. Folic acid supplementation prevents phenytoin-induced gingival overgrowth in children (PubMed)

Folic acid supplementation prevents phenytoin-induced gingival overgrowth in children Gingival overgrowth is an important adverse effect of phenytoin (PHT) therapy, occurring in about half of the patients. This study aimed to evaluate the effect of oral folic acid supplementation (0.5 mg/day) for the prevention of PHT-induced gingival overgrowth (PIGO) in children with epilepsy aged 6-15 years on PHT monotherapy for 6 months.This was a randomized, double-blind, placebo-controlled trial (...) conducted at a tertiary level hospital from May 2008 to June 2009. Children aged 6-15 years started on PHT monotherapy within last 1 month were eligible for inclusion. Preexisting gingival overgrowth, use of other folic acid antagonists, and macrocytic anemia were exclusion criteria. Trial subjects were randomized to receive either folic acid or placebo. The primary outcome measure was incidence of any degree of gingival overgrowth after 6 months of PHT monotherapy. The trial was registered

Full Text available with Trip Pro

2011 EvidenceUpdates

38. Intermittent iron and folic acid supplementation in menstruating women

Intermittent iron and folic acid supplementation in menstruating women WHO | Intermittent iron and folic acid supplementation in menstruating women WHO Regional websites Access Nutrition Menu Intermittent iron and folic acid supplementation in menstruating women Guideline Authors : World Health Organization Publication details Number of pages : 30 Publication date : 2011 Languages : Chinese, English, Farsi, French, Portuguese, Russian, Spanish ISBN : 978 92 4 150202 3 Downloads pdf, 1.24Mb pdf (...) , 661.67kb pdf, 762.61kb Overview This guideline provides global, evidence-informed, recommendations on the intermittent use of iron and folic acid supplements as a public health measure for the purpose of reducing anaemia and improving iron status among menstruating women. The guideline will help Members States and their partners in their efforts to make informed decisions on the appropriate nutrition actions to achieve the Millennium Development Goals, in particular, promotion of gender equality

2011 World Health Organisation Guidelines

39. Systematic review and meta-analysis: No effect of folic acid supplementation on cardiovascular events, cancer or mortality after 5 years in people at increased cardiovascular risk, although homocysteine levels are reduced

Systematic review and meta-analysis: No effect of folic acid supplementation on cardiovascular events, cancer or mortality after 5 years in people at increased cardiovascular risk, although homocysteine levels are reduced No effect of folic acid supplementation on cardiovascular events, cancer or mortality after 5 years in people at increased cardiovascular risk, although homocysteine levels are reduced | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our (...) or password? You are here No effect of folic acid supplementation on cardiovascular events, cancer or mortality after 5 years in people at increased cardiovascular risk, although homocysteine levels are reduced Article Text Therapeutics Systematic review and meta-analysis No effect of folic acid supplementation on cardiovascular events, cancer or mortality after 5 years in people at increased cardiovascular risk, although homocysteine levels are reduced Lydia A Bazzano Statistics from Altmetric.com

2011 Evidence-Based Medicine (Requires free registration)

40. Vitamins B(12), B(6), and folic acid for cognition in older men (PubMed)

Vitamins B(12), B(6), and folic acid for cognition in older men To investigate whether supplementing older men with vitamins B(12), B(6), and folic acid improves cognitive function.The investigators recruited 299 community-representative hypertensive men 75 years and older to a randomized, double-blind controlled clinical trial of folic acid, vitamin B(6), and B(12) supplementation vs placebo over 2 years. The primary outcome of interest was the change in the cognitive subscale (...) , p = 0.478). There was a nonsignificant 28% decrease in the risk of cognitive impairment (odds ratio 0.72, 95% confidence interval 0.25-2.09) and dementia (hazard ratio 0.72, 95% confidence interval 0.29-1.78) over 8 years of follow-up.The daily supplementation of vitamins B(12), B(6), and folic acid does not benefit cognitive function in older men, nor does it reduce the risk of cognitive impairment or dementia.This study provides Class I evidence that vitamin supplementation with daily doses

2010 EvidenceUpdates